// App-Quantinova.ai

FRI0335 : THE EFFECT OF TOFACITINIB ON RESIDUAL PAIN IN PATIENTS WITH PSORIATIC ARTHRITIS

Researchers

Presenter

  • M. Dougados

Principal Investigators

  • D. Van der Heijde

  • C. Bingham

  • P. C. Taylor

  • L. Fallon

  • J. Woolcott

  • Y. Brault

  • L. Wang

  • M. Kessouri

Medical Centers

  • Bichat Hospital, Paris, France

  • Leiden University Medical Centre, Leiden, Netherlands

  • The Johns Hopkins University, Baltimore, United States of America

  • University of Oxford, Oxford, United Kingdom

  • Pfizer Canada, Montreal, QC, Canada

  • Pfizer Inc., Collegeville, United States

  • Pfizer Inc., Paris, France

  • Pfizer, Inc, Groton, CT, United States of America

Locations

  • France

  • Netherlands

  • United States

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • C reactive protein

Drug/Treatment

  • Tasocitinib

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT01877668

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved